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ABSTRACT 
Objective: The aim of this study was to identify reasons acute stroke patients did not receive thrombolysis despite meeting Code Stroke activation 
criteria in Cipto Mangunkusumo General Hospital during November 2015 until February 2019. 
Methods: This study retrospectively collected data of adult (aged>18 y old) acute stroke patients admitted to Cipto Mangunkusumo General 
Hospital from November 2015 to February 2019 who met criteria for Code Stroke activation but did not undergo thrombolysis. Patient’ data were 
collected from Code Stroke Registry of Cipto Mangunkusumo General Hospital. 
Results: There were 518 acute stroke patients who had Code Stroke activated in Cipto Mangunkusumo General Hospital from November 2015 to 
February 2019. 76.3% of acute stroke patients did not receive thrombolytic therapy (n=395). Hemorrhage on computed tomography (CT) scan was 
the most common reason patients did not receive thrombolysis. The following most common reasons were low or improved National Institutes of 
Health Stroke Scale (NIHSS) score, family refusal, and exceedance of time window. 
Conclusion: Hemorrhage on CT scan was the most common reason patients did not receive thrombolysis following by low or improved NIHSS 
score, family refusal, and exceedance of time window. 
Keywords: Stroke, Thrombolysis, Code Stroke, Indonesia 




Stroke can be caused either by ischemia or hemorrhage. Ischemic 
stroke holds accounts for 67% of stroke patients while hemorrhagic 
stroke holds the rest (33%) [1]. Despite having a smaller prevalence, 
hemorrhagic stroke had higher mortality than ischemic stroke. 
Yudiarto et al. study found there were 18.3% deaths of hemorrhagic 
stroke patient’s ≤48 h of onset while there were 3.5% deaths of 
ischemic stroke patients [2].  
Code Stroke is a fast response effort to handle stroke time-efficiently in 
order to provide on-time thrombolysis for acute ischemic stroke 
patients to minimize obstacles causing delayed intervention. In Cipto 
Mangunkusumo General Hospital, Code Stroke can be activated with 
onset-to-door time up to 6 h. The purpose of this regulation is to gain 
the best benefits of thrombolysis with the longest onset-to-treatment 
time allowed. The door-to-needle time is based on the National 
Institutes of Health (NIH) recommendation, which is 60 min [3]. 
Despite meeting the eligibility criteria for Code Stroke activation, not all 
patients receive thrombolysis. Messé et al. study found that about one-
quarter of acute ischemic stroke patients in United States failed to have 
thrombolysis performed [4]. Chinese National Stroke Registry data 
showed that only 181 (12.3%) of 1469 eligible acute ischemic stroke 
patients received thrombolysis [5]. There is not much study yet 
identifying reasons for eligible stroke patient not receiving thrombolysis. 
In Indonesia, there is no published study on that area yet.  
The aim of this study was to investigate reasons acute stroke patient 
not receiving thrombolysis despite meeting Code Stroke activation 
criteria in Cipto Mangunkusumo General Hospital. 
MATERIALS AND METHODS 
Subjects and procedures 
This study retrospectively collected data of acute stroke patients 
admitted to Cipto Mangunkusumo General Hospital from November 
2015 to February 2019. Subjects of this study were adult (aged>18 y 
old) acute stroke patients who met criteria for Code Stroke 
activation but did not undergo thrombolytic therapy.  
Collected patients’ data including sex, age, National Institutes of 
Health Stroke Scale (NIHSS) score on arrival, time of symptom onset 
to hospital arrival (onset-to-door time), chief complaint, and reason 
why thrombolytic therapy did not performed on the patient. Data 
were collected from Code Stroke Registry of Cipto Mangunkusumo 
General Hospital. Identity and data of all patients were held 
confidential. 
Statistical analysis 
Data were analyzed statistically using SPSS version 20. Numerical data 
were presented as means and standard deviation if normally distributed 
(p>0.05), and as median and range if not normally distributed. Normality 
of numerical data was tested using Kolmogorov-Smirnov normality test 
due to the number of subject>50. Categorical data were presented as 
frequencies and percentages. 
RESULTS 
There were 518 acute stroke patients who had Code Stroke 
activated in Cipto Mangunkusumo General Hospital from November 
2015 to February 2019. This number included any type of stroke, 
whether it was ischemic or hemorrhagic. 
There were more than three quarters of acute stroke patients who 
did not receive thrombolytic therapy (76.3%, n=395). Most of those 
patients were male (60.5%). Median age of the patients was 56 y old. 
Median onset-to-door time was 175 min. Median National Institutes 
of Health Stroke Scale (NIHSS) score of the patients on arrival was 
10. Loss of consciousness became the most common chief complain 
(37.5%), followed by right-sided weakness and left-sided weakness 
(each, 20.8%). Baseline demographic and clinical characteristics of 
patients were described in table 1. 
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Table 1: Baseline demographic and clinical characteristics of patients 
 n = 395 % 
Demographic 
Age, y* 56.00 (55.05–57.46) 
Sex (female) 156 39.5 
Clinical 
Onset-to-door, min 175 (161–183) 
Initial NIHSS score* 10 (9–11) 
Chief complain 
Loss of consciousness 148 37.5 
Left sided weakness 82 20.8 
Right sided weakness 82 20.8 
Dysarthria 24 6.1 
Dizziness/vertigo 13 3.3 
Aphasia 11 2.8 
Left sided numbness 8 2.0 
Seizure 8 2.0 
Hemifacial weakness 4 1.0 
Right sided numbness 3 0.8 
Visual loss 3 0.8 
Headache 3 0.8 
Memory loss 1 0.3 
Data are presented as n (%) for categorical variables and as median (interquartile range) for numerical variables. NIHSS: National Institutes of 
Health Stroke Scale, *Kolmogorov-Smirnov normality test<0.05. 
 
Reasons acute stroke patients did not receive thrombolytic therapy  
Hemorrhage on computed tomography (CT) scan became the most 
common reason patients did not receive thrombolysis (42.3%). Low 
or improved NIHSS score was the second most common reason, with 
percentage 22.8%. There were 7.8% of patients who did not receive 
thrombolytic therapy due to family refusal. Exceedance of the time 
window became the fourth most common reason (4.1%). Another 
reasons acute stroke patients did not receive thrombolysis could be 
seen in fig. 1. 
  
 
Fig. 1: Reasons acute stroke patients did not receive thrombolysis, CT scan: computed tomography scan, NIHSS: National Institutes of 
Health Stroke Scale, INR: international normalized ratio 
 
DISCUSSION 
Intravenous tissue plasminogen activator (IV tPA) use has increased 
over the past decade as the primary treatment for the management 
of acute ischemic stroke [4, 6]. However, approximately one-third of 
eligible patients did not receive IV tPA due to various reasons [7, 8]. 
Messé stated that up to 1 out of 5 potentially eligible patients did not 
receive treatment with IV tPA [4]. In this study, 76.3% of acute 
stroke patients did not receive thrombolysis (n=395). This finding 
corresponded with Hu et al. study found that only 22.6% of acute 
ischemic stroke patients arrived at the hospital within 2 h of stroke 
onset received intravenous thrombolysis [6].  
In this study, it was found that hemorrhage on computed 
tomography (CT) scan was the most common reason patients did 
not receive thrombolytic therapy (42.3%). This finding 
corresponded with Fugate and Rabinstein stated that intracranial 
hemorrhage was one of the factors limiting the eligibility of acute 
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ischemic stroke patients in receiving IV tPA, as well as recent 
gastrointestinal bleeding, thrombocytopenia, and coagulopathies 
[9]. In Pidaparthi et al. study, hemorrhagic infarct was one of the 
unavoidable factors for nonadministration of thrombolysis in 
ischemic stroke patients alongside massive infarct, gastrointestinal 
bleed, oral anticoagulant usage with prolonged international 
normalized ratio (INR), and recent cataract surgery [10]. Any kind of 
hemorrhage is a contraindication for thrombolytic therapy. In Messé 
study, percentage of CT findings for intracerebral hemorrhage (ICH), 
subarachnoid hemorrhage (SAH), and infarct as a contraindication 
of IV tPA was 5.3% [4]. Prevalence of hemorrhagic stroke in 
Indonesia is still quite high. In Yudiarto et al. study, prevalence of 
hemorrhagic stroke gathered from 11 hospitals in Indonesia was 
32.9% [2]. In 2018, Harris et al. performed study of 18 hospitals in 
Indonesia conducted using Stroke Case Report Form from 2012 to 
2014. Out of 5411 patients, 3627 (67.03%) had ischemic stroke and 
1784 (32.97%) had hemorrhagic stroke [1]. Hypertension was the 
most common risk factor for hemorrhagic stroke (71.2%) and 
ischemic stroke (63.4%) [2, 11]. ICH accounts for approximately 10-
20% of all strokes [12, 13]. One of risk factors for ICH is 
hypertension [14]. Prevalence of hypertension in Indonesia based 
on measurement was 34.1% according to Indonesia Basic Health 
Research 2018 (Riset Kesehatan Dasar/RISKESDAS 2018), which 
was still quite high [15]. Furthermore, Cipto Mangunkusumo 
General Hospital is the national referral center hospital of Indonesia. 
It is the top referral hospital of the health referral system in 
Indonesia. This hospital receives complicated or end-stage patients 
that cannot be treated in other hospitals anymore. This could be 
another reason explaining why percentage of hemorrhagic stroke 
patients in this hospital–obtained from this study–was high. 
The second most common reason patients did not receive 
thrombolysis was low or improved National Institutes of Health Stroke 
Scale (NIHSS) score (22.8%). This finding corresponded with finding 
from Messé et al. and Nalleballe et al. study. Messé et al. study found 
that rapidly improving or mild stroke was the most common reason 
patients failed to have thrombolysis performed (51.4%) [4]. Nalleballe 
et al. study found that minimal deficits were the most common reason 
acute stroke patients did not treated with IV tPA in 2015 and 2016, 
with percentage 42.17% and 49.5%, respectively [16]. In Hu et al. 
study, mild or rapidly improving symptoms was the third most 
common reason (9%) [6]. Khatri et al.’ analysis on the National 
Institute of Neurological Disorders and Stroke (NINDS) tPA Trials 
found a significant number of patients with minimal deficit excluded 
from the trials [17]. This raised the validity of excluding patients with 
minimal deficit from receiving IV tPA.  
Total of 31 patients (7.8%) did not receive thrombolytic therapy due 
to family refusal. This finding corresponded with Nallebelle et al. 
study found that patients or next to kin refusal were the third most 
common reason patients failed to receive IV tPA in 2015 and 2016, 
with percentage 18.02% and 16.50%, respectively [16]. In Hu et al. 
study, patient or family refusal was the reason 74% patients failed to 
receive thrombolytic therapy [6]. This showed that education about 
etiology, symptoms, and treatment of stroke to enhance patients’ 
family knowledge and awareness of the impact of treatment refusal 
needs to be improved to achieve good outcomes of the patients. 
Possibility of communication barrier existence also needs to be 
investigated. Most patients’ family refused thrombolysis to be given 
to the patients due to a chance of bleeding risk following the 
thrombolytic therapy. For financial problems, thrombolysis cost in 
Cipto Mangunkusumo General Hospital is free because there is a 
National Health Insurance in Indonesia that provides financial 
insurance to all of residents in Indonesia. 
Exceedance of time window was the next most common reason, with 
a percentage 4.1%. Patients presented to the hospital outside of the 
time window continued to be an obstacle for IV tPA administration 
[18-21]. In Nallebelle et al. study, exceedance of time window was 
the second most common reason acute stroke patients did not 
receive IV tPA in 2015 and 2016 (22.44% and 22%, respectively) 
[16]. Code Stroke has been developed to minimize delay in 
thrombolysis administration [22]. Cipto Mangunkusumo General 
Hospital has extended onset-to-door time up to 6 h. However, time 
window exceedance still became one of the most common reasons 
limiting the eligibility of patients to receive thrombolytic therapy. 
Knowledge regarding symptoms and treatment of stroke needs to be 
enhanced among the society–Indonesian society in this matter–to 
prevent this delay.  
Our study had a few limitations. There was no follow-up available 
for final diagnosis confirmation of patients who did not receive 
thrombolytic therapy.  
CONCLUSION 
Results of this study showed that hemorrhage on computed 
tomography (CT) scan was the most common reason patients did not 
receive thrombolytic therapy. Intracranial hemorrhage is a 
contraindication for thrombolytic therapy. Prevalence of hemorrhagic 
stroke in Indonesia is still quite high. The next most common reasons 
were low or improved National Institutes of Health Stroke Scale 
(NIHSS) score, family refusal, and exceedance of the time window. 
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